Mones Jodi V, Soff Gerald
Hematology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.
Cancer Treat Res. 2019;179:139-150. doi: 10.1007/978-3-030-20315-3_9.
Chemotherapy-induced thrombocytopenia (CIT) is a frequent complication of cancer therapy, leading to increased risk of bleeding, when the thrombocytopenia is severe (<10,000/mcL). However, the major clinical relevance of CIT is the subsequent delay or dose reduction in chemotherapy. CIT, therefore, leads to reduced relative dose intensity (RDI) of cancer therapy. Reduced RDI has been shown in several studies to impact progression-free survival and other cancer outcomes. While there are a number of factors leading to reduced RDI, CIT is a common cause. We review the causes and clinical manifestations of CIT, the current recommendations for management, and the status of research to develop targeted therapies to treat CIT.
化疗引起的血小板减少症（CIT）是癌症治疗中常见的并发症，当血小板减少严重（<10,000/微升）时，会导致出血风险增加。然而，CIT的主要临床相关性在于随后化疗的延迟或剂量减少。因此，CIT导致癌症治疗的相对剂量强度（RDI）降低。多项研究表明，RDI降低会影响无进展生存期和其他癌症治疗结果。虽然导致RDI降低的因素有很多，但CIT是一个常见原因。我们综述了CIT的病因和临床表现、当前的管理建议以及开发治疗CIT的靶向疗法的研究现状。
